Board Member Leaves IRLAB for Another Assignment
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Cyberlux Corporation21.1.2022 17:32:37 CET | Press release
Cyberlux Corporation Announces Mr. Chris Damvakaris as Chief Revenue Officer to Lead the Revenue Growth Plans and Strategic Partnerships for the Advanced Digital Technology Company
Episode Six18.1.2022 15:04:37 CET | Press release
Third Anniversary of Episode Six and HSBC's Partnership Shows the Power of Banks and Fintechs Working Together
XPhyto Therapeutics Corp. 17.1.2022 09:06:46 CET | Press release
XPhyto Announces Head of Sales, Europe
Loop Industries, Inc.16.1.2022 22:01:39 CET | Press release
Loop Industries Announces Selection of Port-Jérôme, in Normandy, France, as Site for First European Infinite Loop Manufacturing Facility
XPhyto Therapeutics Corp13.1.2022 09:07:06 CET | Press release
XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia
XPhyto Therapeutics Corp. 10.1.2022 09:06:52 CET | Press release
XPhyto Announces New Director of Business Development and Head of Diagnostic Research
Re:NewCell AB (publ)5.1.2022 11:51:32 CET | Press release
Successful Industrial Scale Viscose Filament Yarn Production from 100 Percent Circulose(R)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom